Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw strong trading volume on Thursday. Approximately 4,501 shares changed hands during mid-day trading, a decline of 34% from the previous session’s volume of 6,784 shares. The stock last traded at $14.62 and had previously closed at $14.85.

Analysts Set New Price Targets

AAPG has been the topic of several research reports. JPMorgan Chase & Co. lowered their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research report on Thursday, October 8th. William Blair began coverage on shares of Ascentage Pharma Group International in a research note on Friday. They issued an “outperform” rating for the company. Citigroup initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday. They issued a “buy” rating and a $46.00 price objective for the company. Citizens Jmp started coverage on shares of Ascentage Pharma Group International in a report on Tuesday. They issued a “market outperform” rating and a $35.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Two analysts have rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $43.90.

Ascentage Pharma Group International Stock Up 4.6%

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The company has a fifty day simple moving average of $16.48 and a two-hundred day simple moving average of $19.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $22.24 million during the quarter. As a group, equities research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.